AB Science SA (FR:AB)
:AB
Top Page
AB Science SA
(AB)
Select Model
Select Model
Rating:40Neutral
Price Target:
€1.50
▲(1.35% Upside)
Action:ReiteratedDate:11/06/25
AB Science SA's overall stock score is primarily impacted by its poor financial performance and negative valuation metrics. The technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Proprietary drug platform
A proprietary protein kinase inhibitor platform focused on oncology and neurology provides durable R&D leverage. Platform assets can produce multiple candidates, increase licensing and partnership optionality, and create long-term differentiation if clinical progress continues.
Negative Factors
Negative shareholders' equity
Negative shareholders' equity is a persistent solvency flag: liabilities exceed assets, impairing borrowing capacity and covenant flexibility. This structural weakness raises long-term refinancing and counterparty risk, potentially constraining growth and strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug platform
A proprietary protein kinase inhibitor platform focused on oncology and neurology provides durable R&D leverage. Platform assets can produce multiple candidates, increase licensing and partnership optionality, and create long-term differentiation if clinical progress continues.
Read all positive factors
AB Science SA (AB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€78.23M
Dividend YieldN/A
Average Volume (3M)323.75K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-5.08%
EPS Growth-88.04%
CountryFR
Employees40
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.09
Shares Outstanding66,184,790
10 Day Avg. Volume89,975
30 Day Avg. Volume323,750
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-1.98
Price to Sales (P/S)43.83
P/FCF Ratio127.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€1.10M
AB Science SA Business Overview & Revenue Model
Company Description
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase...
How the Company Makes Money
AB Science generates revenue primarily through the development and commercialization of its pharmaceutical products. The company focuses on advancing its drug candidates through clinical trials, and once approved, it can either sell these products...
AB Science SA Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.03M | 1.07M | 970.00K | 958.00K | 1.61M | 1.58M |
| Gross Profit | 1.13M | 1.25M | 587.00K | 927.00K | 1.50M | 1.51M |
| EBITDA | -4.47M | -4.92M | -12.80M | -13.41M | -17.36M | -17.10M |
| Net Income | -8.54M | -7.83M | -10.05M | -13.62M | -14.46M | -15.04M |
Balance Sheet | ||||||
| Total Assets | 21.22M | 23.18M | 25.50M | 23.84M | 21.27M | 29.69M |
| Cash, Cash Equivalents and Short-Term Investments | 5.03M | 7.99M | 6.07M | 7.27M | 8.72M | 20.66M |
| Total Debt | 19.08M | 18.47M | 19.10M | 23.96M | 8.35M | 7.06M |
| Total Liabilities | 48.54M | 46.93M | 46.51M | 59.51M | 44.47M | 49.24M |
| Stockholders Equity | -27.32M | -23.75M | -21.01M | -35.67M | -23.20M | -19.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.08M | 370.00K | -17.22M | -18.11M | -17.74M | -13.88M |
| Operating Cash Flow | -6.88M | 525.00K | -16.87M | -17.47M | -17.18M | -13.51M |
| Investing Cash Flow | -189.00K | -136.00K | -614.00K | -360.00K | -590.00K | -277.00K |
| Financing Cash Flow | 2.97M | 1.53M | 16.27M | 16.39M | 5.84M | 28.73M |
AB Science SA Technical Analysis
Negative
1.48
Price Trends
1.30
Negative
1.29
Negative
1.29
Negative
Market Momentum
-0.03
Negative
41.68
Neutral
65.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Negative. The current price of 1.48 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.30, and above the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.68 is Neutral, neither overbought nor oversold. The STOCH value of 65.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AB.
AB Science SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €202.69M | -2.10 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €73.80M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
46 Neutral | €108.94M | -2.91 | -658.91% | ― | -75.86% | -30.54% | |
46 Neutral | €215.16M | -3.44 | -40.00% | ― | ― | 10.87% | |
40 Neutral | €78.23M | -4.03 | ― | ― | -5.08% | -88.04% |
* Healthcare Sector Average
FR:AB
AB Science SA
1.18
-0.08
-6.19%
FR:IPH
Innate Pharma SA
1.16
-0.46
-28.49%
FR:TNG
Transgene
0.74
0.17
29.82%
FR:OSE
OSE Immunotherapeutics SA
3.29
-1.93
-37.03%
FR:ALSEN
Sensorion SAS
0.42
0.07
20.81%
FR:ABLD
ABL Diagnostics SA
2.84
-2.61
-47.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.